Patterns of relapse following definitive treatment of head and neck squamous cell cancer by intensity modulated radiotherapy and weekly cisplatin

Venla Loimu; Juhani Collan; Leila Vaalavirta; Leif Bäck; Mika Kapanen; Antti Mäkitie; Mikko Tenhunen; Kauko Saarilahti

doi:10.1016/j.radonc.2010.10.015

Patterns of relapse following definitive treatment of head and neck squamous cell cancer by intensity modulated radiotherapy and weekly cisplatin

Radiother Oncol. 2011 Jan;98(1):34-7. doi: 10.1016/j.radonc.2010.10.015. Epub 2010 Nov 11.

Authors

Venla Loimu¹, Juhani Collan, Leila Vaalavirta, Leif Bäck, Mika Kapanen, Antti Mäkitie, Mikko Tenhunen, Kauko Saarilahti

Affiliation

¹ Department of Oncology, Helsinki University Central Hospital, Finland.

PMID: 21074875
DOI: 10.1016/j.radonc.2010.10.015

Abstract

Eighty-three patients with oropharyngeal, hypopharyngeal or laryngeal cancer were treated with concomitant cisplatin 40 mg/m(2) once a week during the radiotherapy and IMRT up to a total dose of 70 Gy. The 2-year rate of local control, overall survival and disease specific survival were 84%, 82% and 89%, respectively. The corresponding 5-year Kaplan-Meier estimates were 79%, 69% and 76%.

MeSH terms

Adult
Aged
Antineoplastic Agents / administration & dosage*
Carcinoma / mortality
Carcinoma / therapy
Carcinoma, Squamous Cell
Cisplatin / administration & dosage*
Cisplatin / adverse effects
Combined Modality Therapy
Female
Head and Neck Neoplasms / mortality
Head and Neck Neoplasms / therapy
Humans
Male
Middle Aged
Neoplasms, Squamous Cell / mortality
Neoplasms, Squamous Cell / therapy
Radiotherapy, Intensity-Modulated* / adverse effects
Squamous Cell Carcinoma of Head and Neck

Substances

Antineoplastic Agents
Cisplatin